Molecular adsorbent recirculating system treatment for acute liver failure
May 11, 2010 by admin · Leave a Comment
Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account. So far, only a few small non-randomized studies have focused on the cost-utility and the health-related quality of life of MARS-treated acute-on-chronic liver failure patients. Currently, there are no studies on the health-related quality or cost-utility of MARS treatment in acute liver failure (ALF).
Researchers make advances in understanding causes, treatments and outcomes of liver disease
May 1, 2010 by admin · Leave a Comment
Contact: Amy Levey
alevey@gymr.com
202-745-5116
Digestive Disease Week
Health outcomes explored at DDW 2010
Vitamin E effective for ’silent’ liver disease
April 29, 2010 by admin · Leave a Comment
Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center Read more
Hormone mimic reduces liver damage caused by common genetic kidney disease
April 28, 2010 by admin · Leave a Comment
Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology Read more
Molecular mechanism underlying natural taurine protection against hepatic fibrosis
April 19, 2010 by admin · Leave a Comment
Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body. Taurine has a protective effect on various types of liver injury. It has been clear that the antifibrotic mechanism of taurine may involve its inhibition of the activation and proliferation of HSCs. However, the molecular mechanism of taurine-mediated antifibrotic activity is largely unknown.
Innovation in liver disease
April 16, 2010 by admin · Leave a Comment
Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver Read more
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver Read more
New studies help establish potential of artificial liver support devices
April 15, 2010 by admin · Leave a Comment
Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver Read more
Study shows potential benefit of dark chocolate for liver disease patients
April 14, 2010 by admin · Leave a Comment
Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Vienna, Austria, Thursday 15 April: Doctors could soon be prescribing a dose of dark chocolate to help patients suffering from liver cirrhosis and from dangerously high blood pressure in their abdomen, according to new research presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria.
Targeted delivery of losartan reduces liver inflammation and scarring
February 28, 2010 by admin · Leave a Comment
Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell Read more
